The rise of Sildenafil initially drove a period of growth for pharma, but recent changes present a murky scenario for investors. Off-patent versions are reducing earnings, and persistent legal battles add further https://diegocvbr859205.win-blog.com/22442152/sildenafil-and-pharma-a-precarious-investment